CTLA4 and hereditary sensory and autonomic neuropathy: Among the various irAEs, checkpoint inhibitor pneumonitis (CIP) is generally uncommon, with a frequency of 3% to 5% for PD-1/PD-L1 inhibitors and 1% for CTLA-4 inhibitors in clinical trial settings,[7–9] but if not treated timely, it is a potentially fatal or life-threatening complication, accounting for 28% of ICI-induced deaths.[10] However, it should be noted that the incidence of CIP was up to 13% to 19% in real-world practice,[11,12] which is much higher than those observed in clinical studies.